Capital Analysts LLC’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Capital Analysts LLC’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-337	Closed	-$13K	–	1486
2025 Q3	$13K	Sell	337 -1	-0.3%	-$36	﹤0.01%	1149
2025 Q2	$11K	Sell	338 -339	-50%	-$10.7K	﹤0.01%	1124
2025 Q1	$22K	Sell	677 -3,046	-82%	-$116K	﹤0.01%	970
2024 Q4	$145K	Sell	3,723 -577	-13%	-$24.2K	0.01%	541
2024 Q3	$194K	Sell	4,300 -40	-0.9%	-$1.79K	0.01%	471
2024 Q2	$181K	Sell	4,340 -325	-7%	-$13.6K	0.01%	471
2024 Q1	$212K	Sell	4,665 -18	-0.4%	-$820	0.01%	431
2023 Q4	$217K	Buy	4,683 +384	+9%	+$15.7K	0.01%	407
2023 Q3	$175K	Buy	4,299 +279	+7%	+$12.7K	0.01%	409
2023 Q2	$195K	Buy	4,020 +267	+7%	+$13.4K	0.01%	382
2023 Q1	$185K	Sell	3,753 -532	-12%	-$27.4K	0.01%	390
2022 Q4	$217K	Buy	4,285 +1,265	+42%	+$65.2K	0.01%	390
2022 Q3	$152K	Buy	3,020 +666	+28%	+$37.6K	0.01%	390
2022 Q2	$115K	Sell	2,354 -338	-13%	-$17.1K	0.01%	414
2022 Q1	$162K	Buy	+2,692	New	+$170K	0.01%	362

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Capital Analysts LLC's GNOM Position: Q4 2025 in Review

Capital Analysts LLC sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2025, closing a stake of 337 shares — an estimated $13K sold.

Capital Analysts LLC first reported a position in GNOM in Q1 2022 and held it in 15 quarters. The position peaked at $217K in Q4 2023. 40 funds tracked by Wall St. Rank hold GNOM as of Q4 2025.

Capital Analysts LLC reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
Capital Analysts LLC sold 337 Global X Genomics & Biotechnology ETF shares in Q4 2025, an estimated $13K.
Capital Analysts LLC first reported a position in Global X Genomics & Biotechnology ETF in Q1 2022 and held it in 15 quarters.
Capital Analysts LLC's Global X Genomics & Biotechnology ETF position peaked at $217K in Q4 2023.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2025.

Based on Capital Analysts LLC's 13F filing for Q4 2025, filed 11 Feb 2026.